ESSA Bancorp(US:ESSA) Prnewswire·2025-02-28 10:45Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Lawsuit Details - The complaint claims that ESSA Pharma Inc. made false statements regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the company's public statements about masofaniten's prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].